Cargando…

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6–10 months. We conducted a phase II trial of upfront 5-day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or multifocal glioblastoma. Patients received up to four cycles of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lou, Emil, Peters, Katherine B, Sumrall, Ashley L, Desjardins, Annick, Reardon, David A, Lipp, Eric S, Herndon, James E, Coan, April, Bailey, Leighann, Turner, Scott, Friedman, Henry S, Vredenburgh, James J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639657/ https://www.ncbi.nlm.nih.gov/pubmed/23634286 http://dx.doi.org/10.1002/cam4.58

Ejemplares similares

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018)

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
por: Affronti, Mary Lou, et al.
Publicado: (2016)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

Current available therapies and future directions in the treatment of malignant gliomas
por: Desjardins, Annick, et al.
Publicado: (2009)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
por: Chen, Zhaoyan, et al.
Publicado: (2020)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
por: Reardon, D A, et al.
Publicado: (2009)

A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
por: Sampson, John H., et al.
Publicado: (2012)

SPCR-03 NEUROCOGNITIVE OUTCOMES FROM PHASE 1 TRIAL OF BMX-001 IN COMBINATION WITH CONCURRENT RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA PATIENTS
por: Peters, Katherine, et al.
Publicado: (2022)

Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients
por: Mitchell, Duane A., et al.
Publicado: (2015)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
por: Mathew Thomas, Vinay, et al.
Publicado: (2019)

Clinical Outcomes of Upfront Primary Tumor Resection in Synchronous Unresectable Metastatic Colorectal Cancer
por: Shin, Ji Eun, et al.
Publicado: (2023)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
por: Li, Ze-Yang, et al.
Publicado: (2021)

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma
por: Boyar, Michelle S., et al.
Publicado: (2008)

Complete Radiologic Response in an Anaplastic Oligodendroglioma Treated with Temozolomide and Bevacizumab
por: Katz, Artur, et al.
Publicado: (2009)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Adjunctive perampanel for glioma-associated epilepsy()
por: Dunn-Pirio, Anastasie M., et al.
Publicado: (2018)

Informational needs assessment of non‐Hodgkin lymphoma survivors and their physicians
por: Friedman, Daphne R., et al.
Publicado: (2010)

Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2020)

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma
por: Shi, Ying, et al.
Publicado: (2021)

Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma
por: Franco, Abigail I., et al.
Publicado: (2018)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Treatment of Unresectable Differentiated Thyroid Carcinoma With Upfront External Radiotherapy and Salvage Surgery: A STROBE-Compliant Retrospective Cohort Study
por: Carrillo, José F., et al.
Publicado: (2021)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

The role of upfront primary tumor resection in asymptomatic patients with unresectable stage IV colorectal cancer: A systematic review and meta-analysis
por: Liang, Zongyu, et al.
Publicado: (2023)

Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report
por: Omar, Ayman I
Publicado: (2012)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report
por: OKITA, YOSHIKO, et al.
Publicado: (2015)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
por: Carter, Tonia C., et al.
Publicado: (2018)

Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child
por: Dutta, Pinaki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_389nap48h47fokqhgi1en4eujm